American Association for Cancer Research
00085472can113603-sup-t2_63k.pdf (63.41 kB)

Supplementary Table 2 from Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma

Download (63.41 kB)
journal contribution
posted on 2023-03-30, 20:43 authored by Kelly C. Goldsmith, Michelle Gross, Susan Peirce, Dema Luyindula, Xueyuan Liu, Annette Vu, Michael Sliozberg, Rong Guo, Huaqing Zhao, C. Patrick Reynolds, Michael D. Hogarty

PDF file - 63K, Fresh frozen neuroblastoma sample characteristics



Neuroblastoma is a childhood tumor in which transient therapeutic responses are typically followed by recurrence with lethal chemoresistant disease. In this study, we characterized the apoptotic responses in diverse neuroblastomas using an unbiased mitochondrial functional assay. We defined the apoptotic set point of neuroblastomas using responses to distinct BH3 death domains providing a BH3 response profile and directly confirmed survival dependencies. We found that viable neuroblastoma cells and primary tumors are primed for death with tonic sequestration of Bim, a direct activator of apoptosis, by either Bcl-2 or Mcl-1, providing a survival dependency that predicts the activity of Bcl-2 antagonists. The Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 showed single-agent activity against only Bim:Bcl-2 primed tumor xenografts. Durable complete regressions were achieved in combination with noncurative chemotherapy even for highest risk molecular subtypes with MYCN amplification and activating ALK mutations. Furthermore, the use of unique isogenic cell lines from patients at diagnosis and at the time of relapse showed that therapy resistance was not mediated by upregulation of Bcl-2 homologues or loss of Bim priming, but by repressed Bak/Bax activation. Together, our findings provide a classification system that identifies tumors with clinical responses to Bcl-2 antagonists, defines Mcl-1 as the principal mediator of Bcl-2 antagonist resistance at diagnosis, and isolates the therapy resistant phenotype to the mitochondria. Cancer Res; 72(10); 2565–77. ©2012 AACR.

Usage metrics

    Cancer Research



    Ref. manager